Hubbry Logo
Osmotic-controlled release oral delivery systemOsmotic-controlled release oral delivery systemMain
Open search
Osmotic-controlled release oral delivery system
Community hub
Osmotic-controlled release oral delivery system
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Osmotic-controlled release oral delivery system
Osmotic-controlled release oral delivery system
Osmotic-controlled release oral delivery system
View on Wikipedia
from Wikipedia
A 54 mg tablet of Concerta, which uses OROS technology. 22% of the drug is contained in the red overcoat, while the remaining 78% is split between two drug layers of differing concentration. The tablet uses an additional push layer that expands as water enters the tablet via the osmotic membrane. The drug is expelled via the laser-drilled hole visible on the left side of the tablet.

The osmotic-controlled release oral delivery system (OROS) is an advanced controlled release oral drug delivery system in the form of a rigid tablet with a semi-permeable outer membrane and one or more small laser drilled holes in it. As the tablet passes through the body, water is absorbed through the semipermeable membrane via osmosis, and the resulting osmotic pressure is used to push the active drug through the laser drilled opening(s) in the tablet and into the gastrointestinal tract. OROS is a trademarked name owned by ALZA Corporation, which pioneered the use of osmotic pumps for oral drug delivery.[1][2][3]

Rationale

[edit]

Pros and cons

[edit]

Osmotic release systems have a number of major advantages over other controlled-release mechanisms. They are significantly less affected by factors such as pH, food intake, GI motility, and differing intestinal environments. Using an osmotic pump to deliver drugs has additional inherent advantages regarding control over drug delivery rates. This allows for much more precise drug delivery over an extended period of time, which results in much more predictable pharmacokinetics. However, osmotic release systems are relatively complicated, somewhat difficult to manufacture, and may cause irritation or even blockage of the GI tract due to prolonged release of irritating drugs from the non-deformable tablet.[1][4][5][6][7][8][9]

Oral osmotic release systems

[edit]

Single-layer

[edit]
An illustration of the different components of the Elementary Osmotic Pump.

The Elementary Osmotic Pump (EOP) was developed by ALZA in 1974, and was the first practical example of an osmotic pump based drug release system for oral use.[1][2][10][11][12] It was introduced to the market in the early 1980s in Osmosin (indomethacin) and Acutrim (phenylpropanolamine), but unexpectedly severe issues with GI irritation and cases of GI perforation led to the withdrawal of Osmosin.[1]

Merck & Co. later developed the Controlled-Porosity Osmotic Pump (CPOP) with the intention of addressing some of the issues that led to Osmosin's withdrawal via a new approach to the final stage of the release mechanism.[1] Unlike the EOP, the CPOP had no pre-formed hole in the outer shell for the drug to be expelled out of. Instead, the CPOP's semipermeable membrane was designed to form numerous small pores upon contact with water through which the drug would be expelled via osmotic pressure. The pores were formed via the use of a pH insensitive leachable or dissolvable additive such as sorbitol.[13]

Multi-layer

[edit]
An illustration of the different components of the Push-Pull Osmotic Pump.

Both the EOP and CPOP were relatively simple designs, and were limited by their inability to deliver poorly soluble drugs.[1] This led to the development of an additional internal "push layer" composed of material (a swellable polymer) that would expand as it absorbed water, which then pushed the drug layer (which incorporates a viscous polymer for suspension of poorly soluble drugs) out of the exit hole at a controlled rate.[1][4] Osmotic agents such as sodium chloride, potassium chloride, or xylitol are added to both the drug and push layers to increase the osmotic pressure.[1][4][5] The initial design developed in 1982 by ALZA researchers was designated the Push-Pull Osmotic Pump (PPOP), and Procardia XL (nifedipine) was one of the first drugs to utilize this PPOP design.[1][2]

An animation illustrating the exterior/interior compositions of a tablet of Concerta, a PSOP OROS design.

In the early 1990s, an ALZA-funded research program began to develop a new dosage form of methylphenidate for the treatment of children with attention deficit hyperactivity disorder (ADHD).[14] Methylphenidate's short half-life required multiple doses to be administered each day to attain long-lasting coverage, which made it an ideal candidate for the OROS technology. Multiple candidate pharmacokinetic profiles were evaluated and tested in an attempt to determine the optimal way to deliver the drug, which was especially important given the puzzling failure of an existing extended-release formulation of methylphenidate (Ritalin SR) to act as expected. The zero-order (flat) release profile that the PPOP was optimal at delivering failed to maintain its efficacy over time, which suggested that acute tolerance to methylphenidate formed over the course of the day. This explained why Ritalin SR was inferior to twice-daily Ritalin IR, and led to the hypothesis that an ascending pattern of drug delivery was necessary to maintain clinical effect. Trials designed to test this hypothesis were successful, and ALZA subsequently developed a modified PPOP design that utilized an overcoat of methylphenidate designed to release immediately and rapidly raise serum levels, followed by 10 hours of first-order (ascending) drug delivery from the modified PPOP design. This design was called the Push-Stick Osmotic Pump (PSOP), and utilized two separate drug layers with different concentrations of methylphenidate in addition to the (now quite robust) push layer.[1][14]

An illustration of the different inner components of a tablet of Concerta, a PSOP OROS design.

List of OROS medications

[edit]

OROS medications include:[1][3][4][7]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Osmotic-controlled release oral delivery system

View on Grokipedia
from Grokipedia
The osmotic-controlled release oral delivery system (OROS) is an advanced technology designed for that employs to achieve controlled, zero-order release of active pharmaceutical ingredients over a prolonged period, typically 12–24 hours, thereby maintaining consistent plasma drug concentrations and minimizing fluctuations associated with immediate-release formulations. Developed initially by the Alza Corporation in the 1970s, OROS systems represent a cornerstone of controlled-release technologies, with the elementary osmotic pump (EOP) patented in as the foundational design. The core mechanism relies on : upon ingestion, gastrointestinal fluids permeate a surrounding the tablet core, dissolving an osmotic agent (such as or ) inside, which generates hydrostatic pressure to expel the solution or suspension through a precisely laser-drilled orifice at a rate governed by the membrane's permeability and the osmotic gradient, independent of external factors like , gastrointestinal , or food intake. Key components include the drug layer (often combined with excipients like wicking agents such as sodium lauryl sulfate for enhanced fluid uptake), the osmotic agent to drive imbibition, the coating (typically ), and pore-forming agents to facilitate controlled release. OROS systems offer several variations to accommodate diverse drug properties and therapeutic needs, including the push-pull osmotic pump (introduced in 1984), which features a bilayer structure with a push layer expanding to force drug release from a pull layer, ideal for poorly soluble drugs; the controlled porosity osmotic pump (developed in 1985), where micropores form without pre-drilled orifices; and specialized forms like liquid OROS or colon-targeted systems for site-specific delivery. Advantages of OROS include improved patient compliance through reduced dosing frequency, high in vitro-in vivo correlation for reliable , and protection against under normal conditions, making it suitable for drugs with short half-lives (1–6 hours) that benefit from steady-state . However, limitations exist, such as potential risks of incomplete release or toxicity if the ruptures, challenges in manufacturing the precise coating, and unsuitability for drugs unstable in aqueous environments. Clinically, OROS has been applied to a wide range of therapeutics, including antihypertensives like (Procardia XL) for once-daily treatment of , antidiabetics such as glipizide (Glucotrol XL) for sustained glycemic control, and analgesics like for management, with over a dozen FDA-approved products demonstrating its efficacy in conditions requiring consistent drug exposure. Historical roots trace back to early osmotic studies in the , with the first practical implantable pump emerging in 1955, evolving into modern oral systems that have significantly advanced by enabling tailored release profiles.

Overview

Definition and Purpose

The Osmotic-controlled release oral delivery system (OROS) is an advanced oral technology designed for human administration, featuring a rigid tablet core that contains the active pharmaceutical ingredient, often combined with osmotic agents, encapsulated by a semi-permeable outer membrane. This membrane selectively permits water ingress from the while restricting passage, except through one or more small orifices drilled via or mechanical methods, enabling osmosis-driven release of the in solution form. The core purpose of OROS is to achieve zero-order release kinetics, where the is delivered at a constant rate following an initial lag phase of 0.5 to 1.5 hours, typically sustaining release for 12 to 24 hours to maintain consistent therapeutic plasma levels. This approach minimizes fluctuations between peak and trough concentrations, reduces dosing frequency to once daily, and improves patient adherence, especially for chronic therapies involving medications with short elimination half-lives of 1 to 6 hours. Unlike immediate-release formulations, which exhibit rapid absorption highly dependent on gastrointestinal , , and food presence, OROS ensures delivery independent of these variables, providing more reliable and pharmacokinetic profiles.

Historical Development

The phenomenon of was first observed and described in 1748 by French Jean-Antoine Nollet, who noted the movement of water through a semi-permeable separating alcohol and water, laying the groundwork for understanding osmotic processes. Over a century later, was quantified through experimental measurements by German botanist Wilhelm Pfeffer in 1877 using copper membranes, providing the first reliable data on this force. Jacobus van 't Hoff built on Pfeffer's work in 1887, deriving a theoretical equation relating to solute concentration, akin to the , which formalized the principles essential for later applications. The modern era of osmotic drug delivery began in 1955 with the invention of the Rose-Nelson pump by Australian pharmacologists Sydney Rose and Francis Nelson, an implantable device designed for continuous drug infusion in animals, such as delivering nutrients to sheep rumens, which introduced core osmotic principles like a salt chamber and semi-permeable . In the , the Alza Corporation, under the leadership of pharmaceutical scientist Felix Theeuwes, advanced this concept for , developing the first elementary osmotic pump (EOP) in 1974 as a simplified, tablet-like system for controlled release directly in the . Key innovations followed through a series of s by Alza. In 1976, Alza secured a U.S. for the oral osmotic pump, enabling practical human use with a rigid, bilayer structure that provided zero-order release independent of or . Advancements continued in 1982 with a introducing expandable layers to enhance from the osmotic compartment, improving efficiency for soluble drugs. By 1984, the push-pull osmotic pump was ed, featuring a bilayer osmotic agent that expanded to displace poorly soluble drugs via a piston-like mechanism, broadening applicability. Further refinement came in 1995 with a for osmotic systems, allowing suspension of drugs in cores for better handling of insoluble compounds. Commercialization accelerated in the , with the first OROS product, Osmosin (indomethacin), approved and launched in in 1982, though it was later withdrawn due to gastrointestinal issues; subsequent approvals, such as OROS (Procardia XL) in the U.S. in 1989, established the platform's viability. As of 2022, at least 29 OROS-based drugs had been marketed globally, including treatments for , , and ADHD, with ongoing refinements targeting poorly soluble APIs to expand therapeutic options. A notable milestone was Alza's collaboration with in the 1990s, culminating in the development and 2000 FDA approval of Concerta ( OROS) for ADHD, demonstrating OROS's role in pediatric extended-release formulations.

Principles and Components

Osmotic Mechanism

The osmotic mechanism in osmotic-controlled release oral delivery systems (OROS) relies on the fundamental principle of , which is the spontaneous net movement of across a semi-permeable from a region of lower solute concentration to higher solute concentration, driven by an gradient. (π) is quantified by the : π = iCRT, where i is the (number of particles the solute dissociates into), C is the osmolyte , R is the universal , and T is the absolute temperature. This gradient arises from osmotically active agents (osmogens) within the system's core, creating a thermodynamic driving force for influx independent of the external hydrostatic . In the release process, gastrointestinal fluid permeates the semi-permeable membrane surrounding the core, dissolving the and osmogen to generate an internal differential. This pressure builds hydrostatic force within the rigid core, expelling the saturated drug solution (or suspension) through a precisely sized orifice at a controlled, constant rate. The membrane's selective permeability allows only and minimal solutes to enter while preventing drug , ensuring the release is governed solely by the osmotic influx volume. The system achieves zero-order release kinetics, where the rate remains constant and independent of the external gastrointestinal environment, such as or agitation, after an initial lag phase of 1-2 hours required for hydration and pressure equilibration. The theoretical release rate (dM/dt) is described by the equation: dMdt=A⋅D⋅Δπh\frac{dM}{dt} = \frac{A \cdot D \cdot \Delta\pi}{h} where A is the surface area, D is the water permeability of the , Δπ is the difference across the , and h is the thickness; this rate is modulated by the drug's or suspension concentration in the core. For highly soluble drugs, the release directly correlates with the influx volume, yielding a steady-state profile. A distinctive aspect of the mechanism is the process, whereby incoming water swells the core and generates hydrostatic pressure that suspends insoluble drug particles in the expelled fluid, enabling controlled delivery of poorly water-soluble agents without relying on dissolution alone. The system's structural integrity is preserved in the by the rigid, non-erodible coating, which withstands physiological pressures and prevents premature bursting or uncontrolled release.

Key Components

The drug layer in an osmotic-controlled release oral delivery system (OROS) serves as the primary reservoir for the , typically formulated for drugs with a of 1–6 hours that exhibit moderate in gastrointestinal fluids. This layer may include up to 40% API by weight in standard compositions, though higher loadings (60–95%) are possible for specific high-dose formulations, and it often incorporates excipients to ensure compressibility and stability. For APIs with low solubility, the drug layer can accommodate suspendable insoluble particles, where wicking agents such as sodium lauryl sulfate, (PVP), or colloidal are added to promote water channeling and prevent drug agglomeration, facilitating uniform release. Osmotic agents, or osmogens, are hydrophilic substances incorporated into the core to generate the osmotic pressure gradient that drives influx and controlled release, with the osmotic pressure from these agents being a key factor in the system's performance. Common osmogens include inorganic salts such as and , as well as sugars like , , , , , dextrose, or , often used individually or in mixtures (e.g., with ) at concentrations typically ranging from 10% to 50% by weight to achieve effective osmotic gradients without exceeding core solubility limits. The semi-permeable forms the outer coating of the OROS tablet, selectively permeable to while impermeable to solutes and the , thereby regulating the rate of entry into . It is primarily composed of with 32–38% acetyl content, sometimes blended with (PEG) for enhanced flexibility, and applied as a 5–15% coating weight gain via methods using like methylene chloride, acetone, or , resulting in a thickness of approximately 100–300 μm for optimal and . Plasticizers such as , PEG-600, , or dibutyl sebacate (0.01–20% by weight in the ) are included to improve flexibility and reduce during processing and gastrointestinal transit. The delivery orifice is a critical structural feature consisting of one or more precisely drilled holes that allow the solution to exit the core at a controlled rate determined by the osmotic influx. These orifices typically range from 0.6 to 1 mm in , created post-coating using a CO₂ laser at a 10.6 μm wavelength for accuracy or mechanical , ensuring minimal variation in release kinetics. Additional agents enhance the functionality of the core and membrane. Wicking agents, such as sodium lauryl sulfate or PVP, are incorporated into the drug layer (typically 1–10% by weight) to improve water penetration and drug dissolution, particularly for hydrophobic APIs. Pore-forming agents, including , , or (5–95% of membrane additives), are leached out after coating to create controlled micropores (10–100 μm) in variants like controlled porosity systems, allowing gradual water entry while maintaining semi-permeability.

Types of Systems

Elementary Osmotic Pump

The elementary osmotic pump represents the foundational design in osmotic-controlled release oral delivery systems, featuring a single-layer monolithic core in which the active and osmogen—such as or —are uniformly dispersed and compressed into a tablet. This core is then coated with a semi-permeable membrane, typically composed of , that permits water ingress while preventing solute escape. A single delivery orifice, approximately 0.5–1.5 mm in diameter, is drilled into the membrane using mechanical or methods to allow controlled drug expulsion. In operation, gastrointestinal fluids permeate the semi-permeable membrane due to the osmotic gradient created by the osmogen, leading to the dissolution of the within and the of hydrostatic . This forces the saturated solution out through the orifice at a predictable, constant rate, achieving zero-order release kinetics independent of environmental or agitation. A characteristic lag time of 30–60 minutes occurs as the system hydrates and equilibrates, after which 60–80% of the is delivered over a 24-hour period in a controlled manner. The release rate is directly proportional to the orifice dimensions and osmogen concentration, ensuring reproducible performance. This system is particularly suited for water-soluble drugs exhibiting solubility greater than 1 mg/ and a of 1–6 hours, as the osmotic mechanism efficiently solubilizes and expels such compounds without requiring additional modulation. Unlike advanced variants, the elementary osmotic pump employs no separate push layer, relying exclusively on osmotic to drive expulsion, which limits its use to agents without significant swelling tendencies that could disrupt the core integrity. Tablets are typically sized at 10–20 mm in diameter to facilitate while accommodating the necessary core volume. First commercialized in the by Alza Corporation, the elementary osmotic pump was notably applied to indomethacin in the product Osmosin, marking an early milestone in osmotic oral delivery despite its later withdrawal due to formulation issues.

Push-Pull Osmotic Pump

The push-pull osmotic pump represents an advanced iteration of osmotic-controlled release systems, featuring a bilayer tablet core designed to enhance efficiency. Developed by Alza Corporation and first introduced in for applications, this system consists of a drug layer adjacent to an expandable push layer, both enclosed by a coating. The drug layer, comprising 60-80% of the tablet's weight, incorporates the active pharmaceutical ingredient mixed with osmogenic agents to facilitate suspension or solution formation. The push layer, accounting for 20-40% of the weight, contains swellable hydrophilic polymers such as polyethylene oxide, which enable volumetric expansion upon hydration. Upon ingestion, from the enters both layers through the semi-permeable membrane via . In the layer, this creates a concentrated suspension or solution of the , while in the push layer, uptake causes rapid swelling—expanding up to 2-3 times the original volume—and generates hydrostatic (typically 3-5 ) that propels the outward. The entire bilayer is equipped with a single delivery orifice, usually 0.5-0.7 mm in diameter and drilled by or mechanical means on the layer side, through which the is extruded in a controlled manner. This dual-action mechanism ensures near-complete release (approaching 100%) over 24 hours, with minimal initial lag time, as the push layer's expansion complements osmotic forces to maintain consistent hydrostatic delivery independent of or variations. The push-pull design is particularly effective for poorly soluble or insoluble , where traditional osmotic systems might fail due to insufficient solution formation, by relying on mechanical displacement from the expanding push layer to achieve reliable . It accommodates high drug loads up to 60% by weight, making it versatile for both low-solubility and highly soluble compounds, and reduces risks of incomplete through sustained pressure application. This configuration has been widely adopted in commercial products, such as the Concerta system for extended-release hydrochloride, demonstrating its utility in achieving prolonged therapeutic profiles for disorders.

Other Variants

The controlled-porosity osmotic pump () represents a modification of the basic osmotic system, featuring a single-layer tablet core coated with a semi-permeable that incorporates leachable pore-formers, such as at concentrations of 5-15%, which dissolve upon gastrointestinal fluid contact to generate micropores of 10-100 μm in diameter. This design facilitates drug release through a combination of osmotic pressure-driven and across the pores, enabling zero-order kinetics independent of the drug's and variations. Unlike systems requiring laser-drilled orifices, CPOP relies on the controlled dissolution rate of additives to regulate , typically achieving 5-95% for sustained delivery over extended periods. Multi-particulate osmotic systems extend the OROS concept to smaller units, such as coated pellets or mini-tablets (0.5-2 mm in ), where each particle is individually encased in a semi-permeable containing an osmotic agent. Upon hydration, water ingress forms a saturated solution within the core, which is released at a constant rate through pores, promoting uniform distribution in the for improved gastric retention or tailored pulsatile profiles. These systems enhance flexibility in dosing and reduce inter-subject variability compared to monolithic tablets. Delayed or pulsatile variants of osmotic systems, such as sandwich osmotic tablets, incorporate barrier layers between drug compartments and an expandable osmotic push layer to achieve timed release profiles suitable for chronotherapeutic applications. In these designs, a central layer swells osmotically to displace drug from outer compartments through orifices after the barrier dissolves, enabling lag times of several hours followed by controlled bursts. Osmotically driven chronotherapeutic systems further adapt this for circadian-rhythm-aligned delivery, particularly for conditions like or . A specialized , the self-emulsifying osmotic release oral (OROS), addresses challenges with lipid-soluble drugs by integrating , such as glycerol-based emulsifiers, into the core formulation. Upon osmotic release in the , these agents spontaneously form oil-in-water microemulsions (droplet sizes 20-100 nm), enhancing drug and while maintaining zero-order release kinetics. This variant is particularly effective for poorly water-soluble compounds, improving absorption without altering the core osmotic mechanism. These variants emerged prominently post-1990s to enable site-specific delivery, with finely tuned by the dissolution kinetics of incorporated additives, often yielding 80-90% release efficiency .

Advantages and Limitations

Advantages

Osmotic-controlled release oral delivery systems (OROS) provide therapeutic consistency through zero-order release kinetics, which maintain steady plasma concentrations and minimize fluctuations between peak and trough levels, thereby reducing side effects associated with high peak concentrations. This controlled release profile ensures that levels remain within the therapeutic , between the minimum effective concentration and maximum safe concentration, for extended periods. Additionally, OROS systems exhibit a high in vitro-in vivo (IVIVC), often achieving Level A predictability with coefficients exceeding 0.99, which supports reliable translation of dissolution data to clinical performance. A key advantage of OROS is its physiological independence, as drug release remains unaffected by gastrointestinal pH variations, the presence of , or transit time through the digestive tract, leading to consistent across diverse conditions. This robustness stems from the osmotic pressure-driven mechanism, which operates reliably in the variable environment of the gut, typically achieving bioavailability rates in the range of 70-95% for compatible formulations. Such independence enhances the predictability and efficacy of dosing, particularly for drugs sensitive to environmental factors. OROS improves patient compliance by enabling once-daily dosing that provides 24-hour therapeutic coverage, significantly reducing the pill burden for chronic conditions such as and attention-deficit/hyperactivity disorder (ADHD). This extended release profile not only simplifies regimens but also enhances adherence by minimizing the frequency of administration and associated disruptions. Furthermore, the system's versatility allows formulation with drugs spanning a wide range of aqueous solubilities, from highly soluble to poorly soluble compounds, and offers protection against enzymatic or acidic degradation for sensitive active pharmaceutical ingredients. In terms of tolerability, OROS reduces gastrointestinal irritation compared to immediate-release formulations by delivering the drug gradually through a controlled orifice rather than in a bolus, which mitigates local exposure and side effects like gastric upset. Long-term cost-effectiveness is another benefit, as fewer doses per day lower overall treatment expenses and improve resource utilization in chronic therapies.

Limitations

One significant technical risk associated with osmotic-controlled release oral delivery systems (OROS) is , where defects in the semi-permeable or blockages in the delivery orifice can lead to uncontrolled and rapid release of the entire , potentially causing . While OROS systems are generally resistant to environmental factors, some formulations may exhibit increased release in the presence of alcohol, potentially leading to , particularly for opioids. This issue arises primarily from inconsistencies in the coating process, which can compromise integrity and result in higher-than-intended concentrations in the bloodstream. Additionally, reactions have been reported in rare cases with certain active ingredients in OROS formulations, such as skin eruptions with , manifesting as allergic responses. Design constraints further limit the applicability of OROS, as these systems are generally restricted to drugs that do not or degrade the semi-permeable membrane, requiring compatibility with non-erodible formulations. Moreover, once ingested, the non-retrievable nature of OROS tablets makes it challenging to terminate drug release if adverse effects occur, as the device cannot be easily removed or deactivated after administration. Manufacturing OROS involves high precision in processes like for the orifice and uniform coating, which demand specialized equipment and to ensure consistent performance. These complexities contribute to elevated production costs, typically higher than those for conventional matrix tablets due to additional steps and materials. can also pose challenges, particularly for low-dose s, where achieving precise osmotic gradients and uniform drug distribution requires meticulous adjustments. Physiologically, OROS systems exhibit an initial lag time of approximately 0.5 to 2 hours as gastrointestinal fluids imbibe into the core to initiate , which may delay therapeutic onset and render them unsuitable for acute conditions requiring immediate relief. They are also inappropriate for highly potent toxins, where even minor variations in release could amplify risks of overdose or systemic .

Applications

Commercial Medications

One prominent example of an OROS-based medication is Concerta (methylphenidate HCl), which employs a push-pull osmotic system to provide controlled release for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adults. Available in doses ranging from 18 mg to 72 mg, it delivers the drug over approximately 12 hours, enabling once-daily dosing, and was approved by the FDA in 2000. Ditropan XL (oxybutynin chloride) utilizes an elementary osmotic pump design to manage symptoms, including urinary urgency, frequency, and incontinence. Offered in 5 mg to 30 mg strengths, it provides 24-hour controlled delivery through , reducing peak-related side effects compared to immediate-release formulations. For cardiovascular conditions, Procardia XL () is an extended-release formulation using osmotic technology to treat and , delivering the at a steady rate to minimize vasodilation peaks and associated adverse effects like . Similarly, Covera-HS (verapamil HCl) applies OROS for once-daily management of and , providing consistent plasma levels over 24 hours to support chronotherapeutic dosing. In diabetes management, Glucotrol XL (glipizide) leverages an osmotic gradient in its bi-layer core to achieve once-daily glycemic control in patients, with available doses of 2.5 mg to 10 mg that promote steady insulin release from pancreatic beta cells. Additional OROS products include Exalgo ( HCl extended-release) for moderate to severe in opioid-tolerant patients, utilizing OROS technology for 24-hour delivery, and Invega () for and , which employs OROS to maintain therapeutic levels with once-daily administration. As of 2025, over 15 FDA-approved OROS formulations are available, with many originating from Alza Corporation (now integrated into ).

Clinical and Research Developments

Clinical studies on osmotic-controlled release oral delivery systems (OROS) have demonstrated improved adherence and reduced potential compared to immediate-release formulations. In a involving children with (ADHD), OROS showed superior efficacy and tolerability over immediate-release methylphenidate, particularly among with poor adherence to the latter, leading to better symptom control and compliance. For opioids, post-marketing surveillance studies in the 2010s evaluated OROS extended-release and found low relative rates in high-risk populations, attributed to its tamper-resistant that hinders extraction and misuse. Similarly, the reformulation of OxyContin as an abuse-deterrent extended-release product resulted in a 27% decrease in and addiction diagnoses among commercially insured from 2011 to 2015, highlighting its role in mitigating misuse. Recent research trends emphasize enhancing OROS through and sustainable materials. Integration of with osmotic pumps has enabled targeted delivery and improved performance in controlled-release systems, allowing for precise localization and reduced off-target effects. In the , studies have explored biopolymer-based semi-permeable membranes for osmotic systems, promoting biodegradability to minimize environmental impact while maintaining zero-order release kinetics. A 2022 study in examined embedding poorly water-soluble active pharmaceutical ingredients (APIs) in -based formulations for enhanced solubility, though primarily in orodispersible films; similar strategies have been proposed for osmotic cores to improve of challenging APIs. Ongoing clinical trials and future prospects focus on expanding OROS applications to and advanced therapeutics. Looking ahead, osmotic systems are being adapted for biologics delivery and through smart designs that respond to physiological cues, potentially enabling patient-specific dosing profiles. Hybrid concepts, such as gastroretentive OROS variants with floating push layers, aim to prolong upper gastrointestinal retention for targeted absorption, combining osmotic control with mechanisms to optimize drug release in the . Post-2020 patents continue to advance abuse-deterrent OROS formulations, incorporating features like microsphere encapsulation to further deter tampering.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC9697821/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3407637/
  3. https://onlinelibrary.wiley.com/doi/abs/10.1002/jps.2600641218
  4. https://www.ebsco.com/research-starters/chemistry/nollet-discovers-osmosis
  5. https://www.nobelprize.org/uploads/2018/06/hoff-lecture.pdf
  6. https://chem.libretexts.org/Bookshelves/General_Chemistry/Chem1_%28Lower%29/08%253A_Solutions/8.05%253A__Colligative_Properties_-_Osmotic_Pressure
  7. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/osmotic-controlled-release-oral-delivery-system
  8. https://www.goegoepharm.biz/show-case-13.html
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3164797/
  10. https://patents.google.com/patent/US20050089570A1/en
  11. https://onlinelibrary.wiley.com/doi/full/10.5402/2012/528079
  12. https://ymerdigital.com/uploads/YMER230236.pdf
  13. https://www.japsonline.com/admin/php/uploads/18_pdf.pdf
  14. https://www.sciencedirect.com/topics/nursing-and-health-professions/osmotic-pump
  15. https://www.ijbio.com/articles/an-overview-of-osmotic-drug-delivery-system-an-update-review.pdf
  16. https://www.researchgate.net/publication/285121522_Push-pull_osmotic_tablets_-_An_overview_with_its_commercial_significance
  17. https://www.sciencedirect.com/science/article/pii/S0378517324005507
  18. https://doi.org/10.3390/ph15111430
  19. https://www.sciencedirect.com/science/article/pii/S0928098719304737
  20. https://aapsopen.springeropen.com/articles/10.1186/s41120-017-0014-9
  21. https://www.sciencedirect.com/science/article/pii/S1110093115000319
  22. https://www.researchgate.net/publication/38056334_OROS_Methylphenidate-Induced_Skin_Eruptions
  23. https://www.sciencedirect.com/science/article/abs/pii/S0378517309002166
  24. https://ijppr.humanjournals.com/wp-content/uploads/2019/10/35.HARSHA-P-L-K.-SENTHIL-KUMAR.pdf
  25. https://www.pharmtech.com/view/controlling-drug-release-through-osmotic-systems
  26. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-121_Concerta.cfm
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4971598/
  28. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020897s024lbl.pdf
  29. https://pubmed.ncbi.nlm.nih.gov/10755330/
  30. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019684s023lbl.pdf
  31. https://www.researchgate.net/publication/6771898_Clinical_spectrum_of_the_osmotic-controlled_release_oral_delivery_system_OROS_an_advanced_oral_delivery_form
  32. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020329Orig1s035lbl.pdf
  33. https://labeling.pfizer.com/showlabeling.aspx?id=585
  34. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202144s006lbl.pdf
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC2697506/
  36. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf
  37. https://www.sciencedirect.com/science/article/abs/pii/S0939641109002094
  38. https://onlinelibrary.wiley.com/doi/10.1111/j.1440-1819.2009.01937.x
  39. https://nsuworks.nova.edu/cps_facarticles/1614/
  40. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.390
  41. https://www.mdpi.com/1424-8220/24/21/7042
  42. https://www.mdpi.com/2076-3417/14/4/1383
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC9864024/
  44. http://jopir.in/index.php/journals/article/download/165/232
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC8539558/
  46. https://www.researchgate.net/publication/322237503_Evaluation_of_the_Relative_Abuse_of_an_OROSR_Extended-release_Hydromorphone_HCI_Product_Results_from_three_Post-market_Surveillance_Studies
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.